45 results
8-K
EX-99.1
KRYS
Krystal Biotech Inc
26 Feb 24
Krystal Biotech Announces Fourth Quarter and Full Year 2023
8:04am
Administration (FDA) granted ODD to KB408 for the treatment of AATD.
Preclinical pharmacology data for KB408 was presented at the European Society of Gene & Cell … at www.clinicaltrials.gov under NCT identifier NCT05970497.
Preclinical safety and efficacy data for KB707 was presented in November 2023 at the Society for Immunotherapy
8-K
EX-99.1
KRYS
Krystal Biotech Inc
6 Nov 23
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
7:10am
in multiple oncology models at the Society for Immunotherapy of Cancer’s annual meeting on November 3 and 4, 2023. Combinatorial IL-2 and IL-12
8-K
EX-99.2
83indbb w7l03x09azz
26 Jul 23
Krystal Biotech Announces Pipeline Expansion into Oncology
4:01pm
8-K
EX-99.1
w97zvfb icxh
8 Aug 22
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
4:30pm
8-K
nsnd2w7dnz0
20 May 22
Regulation FD Disclosure
8:26am
8-K
EX-99.1
12zbpsyab 2efmi46ud
20 May 22
Regulation FD Disclosure
8:26am
8-K
EX-99.1
5x8kvicc
9 May 22
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
4:19pm
8-K
EX-99.1
sgoy40nn9y8
22 Mar 22
Regulation FD Disclosure
4:40pm
424B2
fwb85oxy
1 Dec 21
Prospectus for primary offering
5:27pm
424B5
698n5n
29 Nov 21
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
te69v
8 Nov 21
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
4:43pm